US 12,167,991 B2
Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Julien Grassot, Lyons (FR); Cendrine Grangeon, Villeurbanne (FR); and Jordan Dubow, Lyons (FR)
Assigned to Flamel Ireland Limited, Dublin (IE)
Filed by Flamel Ireland Limited, Dublin (IE)
Filed on Jun. 28, 2024, as Appl. No. 18/758,344.
Application 18/758,344 is a continuation of application No. 17/837,740, filed on Jun. 10, 2022.
Application 17/837,740 is a continuation of application No. 16/804,966, filed on Feb. 28, 2020, granted, now 11,400,065.
Claims priority of provisional application 62/857,008, filed on Jun. 4, 2019.
Claims priority of provisional application 62/812,699, filed on Mar. 1, 2019.
Prior Publication US 2024/0350437 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/19 (2013.01) [A61K 9/0053 (2013.01); A61K 9/009 (2013.01); A61K 9/0095 (2013.01)] 23 Claims
 
1. A method of decreasing excessive daytime sleepiness in a human subject, the method comprising:
orally administering a pharmaceutical composition comprising calcium oxybate, magnesium oxybate, and potassium oxybate,
wherein the orally administering occurs only once nightly at least two hours after eating.